Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SERTAD3 antisense RNA 1 (SERTAD3-AS1) is a human long non-coding RNA (lncRNA) classified as an antisense transcript with respect to the SERTAD3 gene[7][5][1]. Antisense RNAs are a subclass of lncRNAs that are transcribed from the opposite strand of a protein-coding gene and can regulate the expression or processing of that gene[9]. There is currently no evidence that SERTAD3-AS1 encodes a protein or is directly involved in disease or drug targeting. Its main biological function, like many antisense lncRNAs, is presumed to be the regulation of its sense counterpart (here, likely SERTAD3) through various possible mechanisms such as RNA interference, transcriptional interference, or epigenetic modulation[4][9]. No established therapeutic, diagnostic, or biomarker roles have yet been assigned to SERTAD3-AS1.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SERTAD3 antisense RNA 1 (SERTAD3-AS1).